

# Nu Pharmas, Inc.

## FOR IMMEDIATE RELEASE

### Contacts:

Steve Parkinson  
President and CEO  
Nu Pharmas, Inc.  
(941) 359 0510  
sparkinson@nupharmas.com

Ted Agne  
The Communications Strategy Group Inc.  
(781) 631 3117  
edagne@comstratgroup.com

### **NU PHARMAS, INC. ACQUIRES RENAISSANCE NUTRACEUTICALS AND APPOINTS STEVE PARKINSON PRESIDENT AND CEO**

**Sarasota, FL and Wilsonville OR, February 1, 2007** – Nu Pharmas, Inc. (NPI), a contract manufacturer of oligonucleotide products as well as a development company of OTC homeopathic products and pharmaceuticals, announced today that it has acquired the assets of Renaissance Nutraceuticals, Inc. (RNI). Terms of the acquisition were not disclosed.

Effective immediately, Steve Parkinson, RNI's Chairman and Chief Executive Officer, has been named President and Chief Executive Officer of the newly merged company. NPI Founding Scientist, Roderic M. K. Dale, Ph.D. also remains with the company as Chairman of the Board and Chief Scientific Officer.

Mr. Parkinson has successfully managed several early-stage biotechnology companies from conception to commercial operation. Most recently he was president and CEO of CereMedix, Inc., now Ischemix, Inc., a drug discovery and development company focused on peptide therapeutics. Previously, he had been president and CEO of TranXenoGen, Inc, an avian transgenics company that he co-founded in 1995 and took public (TXN:LSE) in 2000.

“We are delighted to have Steve with his scientific and company development expertise join us as president and CEO,” Dr. Dale said. “Nu Pharmas is now poised to leverage its exciting products and expand into new and broader commercial markets.

“Steve’s joining us at this critical stage is most welcome timing, Dr. Dale continued. “With his technical and scientific expertise, as well as his skills in internal and external corporate management and partnerships, he clearly has the ideal background to lead us to success.”

Mr. Parkinson added, “I am very pleased to be on board such an exciting venture that offers so many possibilities for product development while capitalizing on current revenue streams. I look forward to the opportunity to lead Nu Pharmas through its next stages of growth and development while bringing more exciting products to market and forging corporate partnerships in the near future.”

#### About Nu Pharmas, Inc.

NPI is a privately held development stage biopharmaceutical company with a novel technology platform and several drugs in development including, a new class of antimicrobials called NuBiotics, as well as a novel array technology and a large family of nanoRNAs that can silence or reduce output from genes including viral replication genes and oncogenes (cancer genes). NPI’s lead product groups:

- NuBiotics, anti-microbial pharmaceutical products, represent a new class of antimicrobials which are effective at killing dangerous antibiotic resistant bacteria

including the deadly strains of methicillin-resistant *Staphylococcus aureus* (MRSA). The NuBiotic compounds also display activity against certain fungal strains. The Company anticipates initiating human clinical trials for topical use of its NU3 compound in the near future for topical indications including; diabetic ulcers and topical infections. Future studies will involve the use of NU3 or other members of the NuBiotic family to treat antibiotic-resistant pulmonary and systemic infections.

Nu Pharmas also encompasses a contract manufacturing division;

- Oligos Etc division (OEI), a contract manufacturer of oligonucleotide compounds.

Founded by Dr. Dale in 1989, the operation has been cash-positive since its formation.

# # #